VALN Stock Nosedives on Mixed Results From Lyme Disease Vaccine Study

Key Takeaways VALN stock dropped 37% after its Lyme vaccine missed a key statistical benchmark in a phase III study.Valneva reported 73.2% efficacy at 28 days, but the confidence interval fell below the required threshold.PF-07307405 showed 74.8% efficacy in a second analysis, supporting planned global filings.Shares of Valneva (VALN) tanked 37% on Monday after the company reported top-line results from the phase III VALOR study, which evaluated its experimental Lyme disease vaccine, PF-07307405 (formerly V ...